Public Controversies

Tenax Therapeutics Faces Class Action Lawsuit Over Levosimendan Trial Results

· GlobeWire Daily Editorial Desk · Source: www.prnewswire.com

2 min read

Key takeawaysRobbins LLP has issued a reminder to investors regarding a class action lawsuit filed against Tenax Therapeutics, Inc. (NASDAQ: TENX). The lawsuit concerns purchasers of Tenax securities between November 13, 2023, and August 7, 2026. According to the complaint, the company allegedly misled investors about the viability and efficacy of its drug candidate…
Tenax Therapeutics Faces Class Action Lawsuit Over Levosimendan Trial Results

Original GlobeWire Daily editorial illustration — not an event photograph.

Robbins LLP has issued a reminder to investors regarding a class action lawsuit filed against Tenax Therapeutics, Inc. (NASDAQ: TENX). The lawsuit concerns purchasers of Tenax securities between November 13, 2023, and August 7, 2026. According to the complaint, the company allegedly misled investors about the viability and efficacy of its drug candidate, levosimendan (TNX-103), which was evaluated for pulmonary hypertension in heart failure patients.

Allegations and Clinical Trial Results

  • Primary Endpoint Missed: On August 10, 2026, Tenax announced that the Phase 3 LEVEL study of oral levosimendan did not meet its primary endpoint of improving the 6-minute walk distance versus placebo, nor did it meet key secondary endpoints.
  • Stock Price Impact: Following the August 10 announcement, Tenax shares reportedly fell approximately 89.77% to close at $1.38 per share.
  • Lawsuit Claims: The complaint alleges that defendants overstated the clinical, regulatory, and commercial prospects of TNX-103 and failed to disclose its actual effectiveness during the class period.

Shareholder Rights and Next Steps

  • Lead Plaintiff Deadline: Investors who suffered significant losses have until December 28, 2026, to seek appointment as lead plaintiff by contacting Robbins LLP.
  • Contingency Representation: The law firm represents investors on a contingency fee basis with no upfront costs.
  • Verification: Investors can verify details of the lawsuit and the class period by reaching out directly to Robbins LLP through their official communication channels or reviewing filings with the U.S. Securities and Exchange Commission.
Share this article
Read the original source: TENX Investors Have Rights - If You Lost Money Investing in Tenax Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

AI-assisted reporting; source claims are attributed and have not been independently verified.

About the author

GlobeWire Daily Editorial Desk — AI-assisted news based on attributed published sources.

More to read